Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853707 | ISIN: US2600031080 | Ticker-Symbol: DOV
Tradegate
21.01.25
21:45 Uhr
190,20 Euro
+2,20
+1,17 %
Branche
Maschinenbau
Aktienmarkt
S&P 500
1-Jahres-Chart
DOVER CORPORATION Chart 1 Jahr
5-Tage-Chart
DOVER CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
188,85189,6521.01.
189,50191,2521.01.
PR Newswire
64 Leser
Artikel bewerten:
(0)

Dover Announces Retirement of Chief Financial Officer; Names Successor

Finanznachrichten News

DOWNERS GROVE, Ill., Dec. 9, 2024 /PRNewswire/ -- Dover Corporation (NYSE: DOV) today announced that Brad Cerepak, Senior Vice President and Chief Financial Officer, has notified the Company that he plans to retire on January 31, 2025. Christopher ("Chris") Woenker, 42, Chief Financial Officer of the Company's Engineered Products and Climate & Sustainability Technologies segments, will succeed Mr. Cerepak as Senior Vice President and Chief Financial Officer, effective January 31, 2025. As part of the Company's transition plan, Mr. Woenker will remain in his current segment CFO roles while working closely with Mr. Cerepak through the 2024 fiscal year financial closing. Mr. Woenker will report to the Chairman and Chief Executive Officer, Richard Tobin.

Mr. Woenker joined the Company in March 2013, first serving as manager and then director in the Financial Planning and Analysis function. He was promoted to business unit CFO in September 2016, and to segment CFO in June 2017. Since then, he has served as CFO for several of the Company's segments, including his current roles as CFO of the Engineered Products and the Climate & Sustainability Technologies segments, giving him a deep understanding of our operating model and our businesses.

Mr. Tobin said, "On behalf of the Board of Directors, I would like to thank Brad for his outstanding leadership and many contributions over the past 15 years. He has been instrumental in driving financial excellence and developing the finance organization across Dover, leaving a strong legacy for the Company to build on. Looking ahead, I am very pleased to announce Chris's appointment. Chris understands well the Dover business culture and has demonstrated strong acumen and exceptional leadership in each of the roles he has held at Dover. His appointment reflects the strength of the Company's long-term succession planning process and the commitment of management and the Board of Directors to develop and promote strong internal talent. I look forward to welcoming him as our new CFO."

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of over $7 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions, and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 65 years, our team of over 24,000 employees takes an ownership mindset, collaborating with customers to redefine what's possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under "DOV." Additional information is available at dovercorporation.com.

Investor Contact:

Media Contact:

Jack Dickens

Adrian Sakowicz

Vice President - Investor Relations

Vice President - Communications

(630) 743-2566

(630) 743-5039

[email protected]

[email protected]

SOURCE Dover

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.